Skip to main content
Retour
RARE logo

Ultragenyx Pharmaceutical Inc.

Qualité des données : 100%
RARE
NASDAQ Healthcare Biotechnology
20,27 €
▲ 0,40 € (2,01%)
Cap. Boursière : 1,96B
Fourchette du Jour
19,53 € 20,33 €
Fourchette 52 Semaines
18,41 € 42,37 €
Volume
2 031 847
Moyenne 50J / 200J
22,84 € / 29,64 €
Clôture Précédente
19,87 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -3,4 0,4
P/B 2,9
ROE % -656,0 3,7
Net Margin % -85,4 3,9
Rev Growth 5Y % 17,6 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
49,90 € +146.2%
Low: 34,00 € High: 63,00 €
BPA Prévisionnel
-4,36 €
CA Est.
750 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 5,58 €
4,11 € – 7,98 €
2,2 B 4
FY2029 3,22 €
2,37 € – 4,60 €
1,7 B 4
FY2028 1,30 €
-1,30 € – 5,44 €
1,4 B 11

Points Clés

Revenue grew 17,64% annually over 5 years — strong growth
Negative free cash flow of -472,00M
PEG of 0,54 suggests growth is underpriced
Capital efficient — spends only 0,89% of revenue on capex

Croissance

Revenue Growth (5Y)
17,64%
Revenue (1Y)20,13%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-656,03%
ROIC-33,55%
Net Margin-85,44%
Op. Margin-79,49%

Sécurité

Debt / Equity
N/A
Current Ratio2,48
Interest Coverage-8,63

Valorisation

P/E Ratio
-3,41
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 20,13% Revenue Growth (3Y) 24,49%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 17,64% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 673,00M Net Income (TTM) -575,00M
ROE -656,03% ROA -37,53%
Gross Margin 83,80% Operating Margin -79,49%
Net Margin -85,44% Free Cash Flow (TTM) -472,00M
ROIC -33,55% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,48
Interest Coverage -8,63 Dividend Yield 0,00%
Valuation
P/E Ratio -3,41 P/B Ratio N/A
P/S Ratio 2,91 PEG Ratio 0,54
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,96B Enterprise Value 2,80B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 673,00M 560,23M 434,25M 363,33M 351,41M
Net Income -575,00M -569,18M -606,64M -707,42M -454,03M
EPS (Diluted) -5,83 -6,29 -8,25 -10,12 -6,70
Gross Profit 564,00M 483,50M 389,04M 335,01M 335,40M
Operating Income -535,00M -535,97M -569,21M -648,92M -381,74M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,53B 1,50B 1,49B 1,55B 1,52B
Total Liabilities 1,61B 1,24B 1,22B 1,19B 599,84M
Shareholders' Equity -80,00M 255,30M 275,41M 352,49M 922,56M
Total Debt 1,28B 40,34M 43,17M 31,59M 41,97M
Cash & Equivalents 434,00M 173,73M 213,58M 132,94M 307,58M
Current Assets 951,00M 817,12M 732,18M 883,90M 856,60M
Current Liabilities 384,00M 344,15M 280,44M 261,21M 181,37M